FATE (Fate Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by FATE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | CINDY TAHL | See Remarks | Sell | — | — |
| 2026-08-05 | Bahram Valamehr | President and CEO | Sell | — | — |
| 2026-06-15 | MATT ABERNETHY | Director | A | — | — |
| 2026-06-15 | ROBERT S EPSTEIN | Director | A | — | — |
| 2026-06-15 | Shefali Agarwal | Director | A | — | — |
| 2026-06-15 | Laura Hamill | Director | A | — | — |
| 2026-06-15 | WILLIAM H RASTETTER | Director | A | — | — |
| 2026-06-15 | Jeremy Green | Director | A | — | — |
| 2026-06-15 | Yuan Xu | Director | A | — | — |
| 2026-06-15 | Karin Jooss | Director | A | — | — |
| 2026-06-15 | Michael Stewart Lee | Director | A | — | — |
| 2026-05-21 | Bahram Valamehr | President and CEO | Sell | — | — |
| 2026-05-21 | CINDY TAHL | See Remarks | Sell | — | — |
| 2026-05-07 | CINDY TAHL | See Remarks | M | — | — |
| 2026-05-06 | ROBERT S EPSTEIN | Director | M | — | — |
| 2026-05-06 | WILLIAM H RASTETTER | Director | M | — | — |
| 2026-04-23 | Jeremy Green | Director | J | — | — |
| 2026-04-22 | Jeremy Green | Director | J | — | — |
| 2026-01-16 | Kamal Adawi | Chief Financial Officer | A | — | — |
| 2026-01-16 | CINDY TAHL | See Remarks | A | — | — |
| 2026-01-16 | Bahram Valamehr | President and CEO | A | — | — |
| 2026-01-12 | Bahram Valamehr | President and CEO | Sell | — | — |
| 2026-01-12 | CINDY TAHL | See Remarks | Sell | — | — |
| 2025-10-21 | Kamal Adawi | Chief Financial Officer | A | — | — |
| 2025-08-05 | CINDY TAHL | See Remarks | Sell | — | — |
| 2025-08-05 | Bahram Valamehr | President and CEO | Sell | — | — |
| 2025-05-30 | Neelufar Mozaffarian | Director | A | — | — |
| 2025-05-30 | MATT ABERNETHY | Director | A | — | — |
| 2025-05-30 | Yuan Xu | Director | A | — | — |
| 2025-05-30 | Michael Stewart Lee | Director | A | — | — |
| 2025-05-30 | Karin Jooss | Director | A | — | — |
| 2025-05-30 | Shefali Agarwal | Director | A | — | — |
| 2025-05-30 | ROBERT S EPSTEIN | Director | A | — | — |
| 2025-05-30 | Jeremy Green | Director | A | — | — |
| 2025-05-30 | JOHN MENDLEIN | Director | A | — | — |
| 2025-05-30 | WILLIAM H RASTETTER | Director | A | — | — |
| 2025-01-16 | Bahram Valamehr | President and CEO | A | — | — |
| 2025-01-16 | CINDY TAHL | See Remarks | A | — | — |
| 2025-01-16 | Jerome Charles Bressi | See Remarks | A | — | — |
| 2025-01-13 | Bahram Valamehr | President and CEO | Sell | — | — |
| 2025-01-13 | CINDY TAHL | See Remarks | Sell | — | — |
| 2025-01-13 | Jerome Charles Bressi | See Remarks | Sell | — | — |
| 2024-12-26 | Jeremy Green | Director | MIXED | — | — |
| 2024-12-16 | Jeremy Green | Director | C | — | — |
| 2024-08-07 | Yuan Xu | Director | Sell | — | — |
| 2024-07-31 | CINDY TAHL | General Counsel and Secretary | A | — | — |
| 2024-07-31 | Bahram Valamehr | Chief R&D Officer | A | — | — |
| 2024-07-31 | Neelufar Mozaffarian | Director | A | — | — |
| 2024-06-11 | Jeremy Green | Director | A | — | — |
| 2024-06-11 | ROBERT S EPSTEIN | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 12,957,222 | — |
| — | Director | 12,884,277 | — |
| — | Director | 2,473,188 | — |
| — | 10%+ Owner | 2,473,188 | — |
| — | 10%+ Owner | 2,169,422 | — |
| — | 10%+ Owner | 1,202,459 | — |
| — | 10%+ Owner | 940,744 | — |
| — | President and CEO | 591,815 | — |
| — | See Remarks | 589,355 | — |
| — | Director | 495,603 | — |
| — | President and CEO | 371,248 | — |
| — | See Remarks | 335,203 | — |
| — | Director | 311,231 | — |
| — | Chief Medical Officer | 140,676 | — |
| — | Chief Technical Officer | 123,705 | — |
| — | Chief Financial Officer | 101,479 | — |
| — | Chief Financial Officer | 100,000 | — |
| — | Chief Scientific Officer | 79,448 | — |
| — | Director | 66,282 | — |
| — | Chief Development Officer | 64,917 | — |
| — | Chief Medical Officer | 46,683 | — |
| — | Chief Commercial Officer | 41,146 | — |
| — | Director | 36,331 | — |
| — | See Remarks | 30,429 | — |
| — | Director | 11,333 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FATE quote page; the site-wide leaderboard is on the insider transactions hub.